Biogen's global chief medical officer told PharmaDispatch the company is undaunted by the historically high failure rates in the development of treatments for Alzheimer’s.
Driven by the 'profound unmet needs of patients'
August 6, 2018 BioPharmaDispatch ExecutiveLatest News
Latest Video
New Stories
-
The Dispatched 'Week in Review' Podcast - 3 October
October 3, 2025 - - Podcast -
The challenge is for our gatekeepers. Can they see beyond the gate?
October 3, 2025 - - Latest News -
Trump administration links MFN and lower prices to faster FDA approvals
October 3, 2025 - - Latest News -
Vertex appoints Elisha Whitfield as senior country manager for Australia and New Zealand
October 2, 2025 - - Latest News -
Race Oncology uncovers novel anticancer mechanism for bisantrene
October 2, 2025 - - Australian Biotech -
Mark Butler announces boost for clinical trial reform, after years of delay
October 2, 2025 - - Latest News -
Pharmac moves to ease access to HIV medicines in New Zealand
October 2, 2025 - - Latest News